Results 81 to 90 of about 8,958 (210)

Reprogramming the tumor microenvironment leverages CD8+ T cell responses to a shared tumor/self antigen in ovarian cancer

Molecular Therapy: Oncolytics, 2023
Tumor antigen-driven responses to weakly immunogenic self-antigens and neoantigens directly affect treatment efficacy following immunotherapy. Using orthotopically grown SV40 T antigen+ ovarian carcinoma in antigen-naive wild-type or TgMISIIR-TAg-Low ...
Anna Mistarz, Marta Winkler, Sebastiano Battaglia, Song Liu, Alan Hutson, Hanna Rokita, Andrea Gambotto, Kunle O. Odunsi, Prashant K. Singh, A.J. Robert McGray, Jianmin Wang, Danuta Kozbor   +11 more
doaj   +1 more source

Theranostic Advancements in Brain Cancer: Promising Approaches for Emerging Therapy

MedComm – Oncology, Volume 5, Issue 2, June 2026.
Strategies for improving intra‐arterial administration (A) and photodynamic therapy in brain cancer (B). Improving intra‐arterial (IA) administration and photodynamic therapy (PDT) for brain cancer involves enhancing tumor targeting and breaching the blood–brain barrier (BBB). Key strategies include super selective catheterization, using osmotic agents
Bipraban Khanra, Manoj Kumar Sarangi
wiley   +1 more source

Coxsackievirus A11 is an immunostimulatory oncolytic virus that induces complete tumor regression in a human non-small cell lung cancer

Scientific Reports, 2023
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide. Innovative treatment is required to improve overall survival rates for advanced NSCLC.
Akira Sakamoto, Hiroyuki Inoue, Shohei Miyamoto, Shun Ito, Yasushi Soda, Kenzaburo Tani   +5 more
doaj   +1 more source

Integrating oncolytic adenoviruses into combination cancer therapy: Mechanisms, advances and clinical outlook

Clinical and Translational Medicine, Volume 16, Issue 5, May 2026.
Oncolytic adenoviruses synergise with chemotherapy, radiotherapy and immunotherapy to enhance anti‐tumour efficacy. Chemotherapy and radiotherapy increase tumour susceptibility and antigen release through DNA damage, while immunotherapy restores T‐cell activity.
Vlad Iova, Gilda Mihaela Iova, Mihail Silviu Tudosie, Ioana Scrobota, Catalin Gabriel Smarandache   +4 more
wiley   +1 more source

Oncolytic Virotherapy of Canine and Feline Cancer [PDF]

, 2014
Cancer is the leading cause of disease-related death in companion animals such as dogs and cats. Despite recent progress in the diagnosis and treatment of advanced canine and feline cancer, overall patient treatment outcome has not been substantially ...
Joseph Cappello, Adelfinger, Marion, Gentschev, Ivaylo, Sandeep S. Patil, Marion Adelfinger, Aladar A. Szalay, Ivan Petrov, Sandeep Patil, Petrov, Ivan, Cappello, Joseph, Patil, Sadeep S., Aladar Szalay, Ivaylo Gentschev, Szalay, Aladar A.   +13 more
core   +1 more source

Oncolytic polio virotherapy of cancer [PDF]

Cancer, 2014
Recently, the century‐old idea of targeting cancer with viruses (oncolytic viruses) has come of age, and promise has been documented in early stage and several late‐stage clinical trials in a variety of cancers. Although originally prized for their direct tumor cytotoxicity (oncolytic virotherapy), recently, the proinflammatory and immunogenic effects ...
Michael C, Brown, Elena Y, Dobrikova, Mikhail I, Dobrikov, Ross W, Walton, Sarah L, Gemberling, Smita K, Nair, Annick, Desjardins, John H, Sampson, Henry S, Friedman, Allan H, Friedman, Douglas S, Tyler, Darell D, Bigner, Matthias, Gromeier   +12 more
openaire   +2 more sources

Dual‐Function Lipid‐Based Nanovector Strategy for Glioblastoma Immunotherapy: STING Activation and M1 Microglia Polarization

Drug Development Research, Volume 87, Issue 3, May 2026.
ABSTRACT Glioblastoma (GBM) remains one of the most lethal brain malignancies because of its highly immunosuppressive tumor microenvironment and the limited penetration of therapeutics across the blood‐brain barrier (BBB). Although recent studies have separately explored STING agonism, microglial reprogramming, and nanocarrier‐based drug delivery, an ...
Mohamed S. Nafie, Mohamed Khaled Diab, Sherif Ashraf Fahmy   +2 more
wiley   +1 more source

TGF-β Inhibition Improves Oncolytic Herpes Viroimmunotherapy in Murine Models of Rhabdomyosarcoma

Molecular Therapy: Oncolytics, 2017
Oncolytic viruses are an emerging class of cancer therapeutics that couple cytotoxicity with the induction of an anti-tumor immune response. Host-virus interactions are complex and modulated by a tumor microenvironment whose immunosuppressive activities ...
Brian Hutzen, Chun-Yu Chen, Pin-Yi Wang, Les Sprague, Hayley M. Swain, Julia Love, Joe Conner, Louis Boon, Timothy P. Cripe   +8 more
doaj   +1 more source

Oncolytic Virotherapy for Cancer: Clinical Experience

, 2021
Oncolytic viruses are a new class of therapeutics which are largely in the experimental stage, with just one virus approved by the FDA thus far. While the concept of oncolytic virotherapy is not new, advancements in the fields of molecular biology and ...
Yuman Fong, Susanne G. Warner, Shyambabu Chaurasiya   +2 more
core   +1 more source

Oncolytic viruses: how “lytic” must they be for therapeutic efficacy?

OncoImmunology, 2019
Oncolytic viruses (OVs) preferentially target and kill cancer cells without affecting healthy cells through a multi-modal mechanism of action. While historically the direct killing activity of OVs was considered the primary mode of action, initiation or ...
Maria Eugenia Davola, Karen Louise Mossman   +1 more
doaj   +1 more source